A warning letter was recently sent by the U.S. FDA to Medline, citing non-compliance with manufacturing quality regulations, marking their second infraction within a two-month timeframe.
A warning letter has been sent by the US FDA to Medline (MDLN.O) regarding non-compliance with manufacturing quality regulations, marking its second infraction within a span of just two months.
Related ↗A powerful earthquake measuring 7.8 magnitude hits the south of Philippines.A second stern warning was issued by the Food and Drug Administration on May 28, highlighting Medline's shortcomings in investigating microbial contamination and maintaining proper cleaning procedures.
The latest development comes on the heels of a previous FDA warning letter issued in April, which highlighted concerns over defective syringes used in cardiovascular procedures.
Read next ↗New Obesity Treatment from Boehringer-Zealand Reduces Visceral Liver Fat Effectively.The FDA expressed concern over Medline's investigation into tainted products, deeming it insufficient and criticizing the company for failing to provide insight into previous corrective measures' ineffectiveness, which could compromise patient well-being.
The company's ReadyCare Waukegan facility, located in Illinois, underwent a thorough inspection, prompting substantial upgrades to its manufacturing procedures and operational systems for maximum quality assurance.
Medline has been instructed by the FDA to conduct a thorough risk evaluation of its production procedures, infrastructure, and machinery, accompanied by a detailed plan for rectification and specific deadlines.
Medline's manufacturing operations have consistently fallen short of proper cleaning and sanitizing protocols, with similar issues detected across its affiliated facilities nationwide recently.
The agency emphasized that repeated shortcomings across various facilities underscore the need for enhanced governance and accountability within Medline's organizational framework.
Medline confirms ongoing collaboration with the FDA, addressing concerns at both its Waukegan plant and additional facilities involved in drug production.
The FDA has warned that failure to resolve this issue could lead to enforcement consequences.
Medline has 15 days to provide a written response to the agency's concerns.
